LLY250110C660000
- 110.44
- 0.000.00%
Eli Lilly and Co Newsroom
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Medicare will cover Eli Lilly and Co's Zepbound for the treatment of sleep apnea.
According to foreign media reports, the USA federal Medical Insurance (Medicare) drug plan will cover Eli Lilly and Co's (LLY.US) weight loss drug Zepbound for the treatment of obstructive sleep apnea. The USA Food and Drug Administration approved Zepbound on December 20 for the treatment of obesity and moderate to severe obstructive sleep apnea, making it the first treatment approved for approximately 20 million patients with this condition. A spokesperson for the Centers for Medicare and Medicaid Services stated that Medicare's Part D program can cover weight loss drugs, provided that such drugs are used for weight loss.
Zentalis Pharma Says FDA Grants Fast Track Status on Azenosertib Cancer Drug Candidate
Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report
Medicare Can Cover Zepbound for Sleep Apnea, Creating a Significant Opportunity for Eli Lilly
Medicare Will Pay for Zepbound for Some Patients. The Costs Could Be Huge -- Barrons.com
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
LLY Falls Around 14% in 3 Months: How to Play the Stock
Express News | Eli Lilly - New Centre Expected to Open in Mid-2025
Express News | Lilly - to Establish New Global Capability Centre in Hyderabad, India
Eli Lilly and Co's Zepbound for the treatment of apnea can be included in the health insurance program.
On January 9, according to CNBC, the USA's Centers for Medicare and Medicaid Services reported that consumers can include Eli Lilly and Co's obesity drug Zepbound, used for treating sleep apnea, in their Medicare plans.
Medicare Expands Coverage of Eli Lilly's Weight-Loss Drug -- WSJ
Express News | CMS: With FDA Approved Use for Zepbound to Treat Obstructive Sleep Apnea, Current Medicare Part D and Medicaid Coverage Rules Apply
Express News | Consumers in the USA can include Eli Lilly and Co's Zepbound, purchased for the treatment of sleep apnea, under Medicare.
'Medicare Can Now Cover Eli Lilly's Zepbound For Sleep Apnea, CMS Says' - CNBC
Novo Nordisk Needs Answers to These 5 Key Questions
Truist Financial Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,029
What Trump's Denmark Tariff Threat Means for Ozempic Drugmaker Novo Nordisk
These Stocks Are Expected to See at Least 25% Revenue Growth in 2025 – Wolfe